Guidelines

Cancer groups offer guidance on musculoskeletal adverse events related to checkpoint inhibitors


 

Vigilance required

Checkpoint inhibitors have been approved by the FDA to treat a variety of cancers, including melanoma, lung cancer, and Hodgkin lymphoma, as well as lung, liver, kidney, and bladder cancers.

Clinicians managing patients on checkpoint inhibitors should always be vigilant because irAE symptoms can be subtle, according to Julie Brahmer, MD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore.

“Everyone has to work as a team, which includes being educated on possible side effects to immunotherapy prior to prescribing it,” said Dr. Brahmer, chair of the ASCO panel and vice chair of the NCCN panel that developed the guidelines.

The guidelines were published Feb. 14 in two documents that are similar in content, but different in format. The ASCO guideline was published in the Journal of Clinical Oncology (doi: 10.1200/JCO.2017.77.6385) and the NCCN Clinical Practice Guidelines in Oncology were posted on the NCCN website.

While the first edition of the guidelines focus specifically on immune checkpoint inhibitors, an update anticipated for 2019 will include guidance on chimeric antigen receptor (CAR) T cell therapy, which is associated with several important side effects, notably cytokine release syndrome.

Pages

Recommended Reading

Treat to target in RA: Finding the right path forward
MDedge Rheumatology
Researchers identify three distinct clinical-histologic-genetic subtypes in RA
MDedge Rheumatology
NIAID proposes 3-pronged plan for universal influenza vaccine
MDedge Rheumatology
Mast cell synovitis: potential target in RA?
MDedge Rheumatology
Immunotherapy regimen influences inflammatory arthritis presentation
MDedge Rheumatology
Xeljanz: FDA panel recommends ulcerative colitis indication
MDedge Rheumatology
Arthritis limits physical activity the most in the South
MDedge Rheumatology
Study links RA flares after joint replacement to disease activity, not medications
MDedge Rheumatology
FDA approves certolizumab label update for pregnancy, breastfeeding
MDedge Rheumatology
TB in 2017: Good news and bad news
MDedge Rheumatology